Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

518 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. Sternberg CN, et al. Among authors: fizazi k. N Engl J Med. 2020 Jun 4;382(23):2197-2206. doi: 10.1056/NEJMoa2003892. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469184 Clinical Trial.
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
Fléchon A, Fizazi K, Gourgou-Bourgade S, Théodore C, Beuzeboc P, Geoffrois L, Mottet N, Chevreau C, Culine S. Fléchon A, et al. Among authors: fizazi k. Anticancer Drugs. 2006 Jul;17(6):705-8. doi: 10.1097/01.cad.0000210337.85526.cc. Anticancer Drugs. 2006. PMID: 16917216
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S; Meta-analysis of Estramustine in Prostate Cancer (MECaP) Trialists' Collaborative Group. Fizazi K, et al. Lancet Oncol. 2007 Nov;8(11):994-1000. doi: 10.1016/S1470-2045(07)70284-X. Epub 2007 Oct 17. Lancet Oncol. 2007. PMID: 17942366
The postchemotherapy PSA surge syndrome.
Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. Thuret R, et al. Among authors: fizazi k. Ann Oncol. 2008 Jul;19(7):1308-1311. doi: 10.1093/annonc/mdn062. Epub 2008 Mar 19. Ann Oncol. 2008. PMID: 18356135 Free article.
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.
Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, Dogliotti L, Conti G, Turesson I, James N, Heidenreich A, Solsona E, Guillem V, Herchenhorn D, Moul J, van Moorselaar J, Coetzee LJ, Wilson A, Bamias A, De Wit R, Chrisofos M. Fitzpatrick JM, et al. Among authors: fizazi k. Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S9-S22. doi: 10.1016/j.critrevonc.2008.07.019. Epub 2008 Aug 23. Crit Rev Oncol Hematol. 2008. PMID: 18723368 Review.
Combining docetaxel with estramustine: back to the future?
Oudard S, Eymard JC, Fizazi K. Oudard S, et al. Among authors: fizazi k. J Clin Oncol. 2009 Mar 1;27(7):1148-9; author reply 1149-50. doi: 10.1200/JCO.2009.21.2274. Epub 2009 Jan 26. J Clin Oncol. 2009. PMID: 19171697 No abstract available.
518 results